OncoGenex Pharmaceuticals

Type: Company
Name: OncoGenex Pharmaceuticals
First reported 11 hours ago - Updated 11 hours ago - 1 reports

OncoGenex completes patient enrollment in Phase III prostate cancer trial

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has announced the completion of patient enrollment in the Phase III AFFINITY trial, which is reportedly designed to evaluate the potential of custirsen to improve survival outcomes in approximately ... [Published Individual.com - 11 hours ago]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

OncoGenex Pharmaceuticals Reaches New 12-Month Low at $2.76 (OGXI)

OncoGenex Pharmaceuticals (NASDAQ:OGXI) hit a new 52-week low during trading on Friday , reports. The stock traded as low as $2.76 and last traded at $2.81, with a volume of 355,570 shares. The stock had previously closed at $3.00.The stock’s 50-day moving ... [Published American Banking News - Forex - Sep 20 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

OncoGenex's Phase III Prostate Cancer Study Fully Enrolled

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into ... [Published Zacks.com - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Ample room available for novel products in metastatic prostate cancer treatment market, says GlobalData Analyst

Despite numerous product launches in the metastatic castration-resistant prostate cancer (mCRPC) treatment market since 2010, ample opportunity still exists for drug developers to claim their stake in the arena, particularly through drugs with novel molecular ... [Published European Pharmaceutical Review - Sep 18 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

OncoGenex Completes Patient Enrollment In Phase 3 Trial Of Custirsen

OncoGenex Pharmaceuticals, Inc. (OGXI: Quote) Tuesday said it has finished patient enrollment in its Phase 3 AFFINITY trial, which evaluates the potential of Custirsen to improve survival outcomes in men with metastatic castrate-resistant prostate cancer ... [Published RTTNews.com - Sep 16 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

By a News Reporter-Staff News Editor at Biotech Week OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the ... [Published Pharmacy Choice - Sep 03 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

OncoGenex Pharmaceuticals : Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

By a News Reporter-Staff News Editor at Biotech Week -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per ... [Published 4 Traders - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

4 Under-$10 Biotech Stocks in Breakout Territory

aDELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers. Read More: Warren Buffett's Top 10 Dividend StocksStocks that are making large moves like these ... [Published The Street Latest - Aug 27 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

OncoGenex Pharmaceuticals appoints vice president and CFO

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has appointed John Bencich as vice president and CFO. John will lead the company's financial and administrative operations, reporting directly to OncoGenex President and CEO Scott Cormack."John ... [Published Individual.com - Aug 23 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 8 reports

OncoGenex's Custirsen Passes First Interim Futility Analysis…

OncoGenex Pharmaceuticals, Inc. ( OGXI - Snapshot Report ) announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of the randomized, open-label phase III ENSPIRIT study on custirsen for the treatment of advanced ... [Published Zacks.com - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

OncoGenex Says Lung Cancer Drug Trial Will Continue

OncoGenex Pharmaceuticals Inc. Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "OncoGenex Says Lung Cancer Drug Trial Will Continue"Search BioPortfolio ... [Published BioPortfolio - Aug 22 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 3 reports

OncoGenex Pharmaceuticals CMO Cindy Jacobs Unloads 5,650 Shares (OGXI)

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CMO Cindy Jacobs unloaded 5,650 shares of OncoGenex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $3.17, for a total transaction of $17,910.50. ... [Published American Banking News - Forex - Aug 15 2014]

Quotes

"OncoGenex' focus is on the science that may lead one day to preventing cancer from evading treatment, and we are pursuing this approach through the ongoing Phase III trials of custirsen and multiple Phase II trials of apatorsen in four different tumor types."
...we are very pleased that ENSPIRIT has passed this important early interim futility analysis," said Scott Cormack, President and CEO of OncoGenex. "We remain strong in our belief that targeting mechanisms of treatment resistance is a critical path forward in the fight against cancer and we continue to actively pursue this approach through the two ongoing Phase 3 trials of custirsen and the seven Phase 2 trials of apatorsen in four tumor types."
"The team at OncoGenex is genuinely committed to making a difference in the lives of people suffering from devastating illnesses. I am honored to join in this mission at this exciting time of execution and growth" commented John Bencich
...Second, there has been no word on the next steps toward approval, other than chief operating officer Julie Smith's  statement:   "We plan to meet with regulators soon for the purpose of defining the next step toward the potential approval of RP103 for Huntington's disease in the U S and Europe."

More Content

All (63) | News (46) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
OncoGenex completes patient enrollment in Phase... [Published Individual.com - 11 hours ago]
OncoGenex Pharmaceuticals Reaches New 12-Month ... [Published American Banking News - Forex - Sep 20 2014]
OncoGenex's Phase III Prostate Cancer Study Ful... [Published Zacks.com - Sep 18 2014]
Ample room available for novel products in meta... [Published European Pharmaceutical Review - Sep 18 2014]
Global Non-small Cell Lung Cancer Market : 2014... [Published MarketResearch.com - Sep 17 2014]
OncoGenex Completes Patient Enrollment In Phase... [Published RTTNews.com - Sep 16 2014]
OncoGenex Announces Completion of Patient Enrol... [Published ADVFN UK - Sep 16 2014]
OncoGenex Announces Completion of Patient Enrol... [Published Financial Services - Sep 16 2014]
Studies Help Refine Management of Prostate Cancer [Published The ASCO Post - Sep 15 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published Pharmacy Choice - Sep 03 2014]
OncoGenex Pharmaceuticals : Announces Update on... [Published 4 Traders - Aug 28 2014]
4 Under-$10 Biotech Stocks in Breakout Territory [Published The Street Latest - Aug 27 2014]
OncoGenex Pharmaceuticals appoints vice preside... [Published Individual.com - Aug 23 2014]
OncoGenex's Custirsen Passes First Interim Futi... [Published Zacks.com - Aug 22 2014]
OncoGenex's Custirsen Passes First Interim Futi... [Published Yahoo! Finance - Aug 22 2014]
Sector Update: Health Care Stocks Mixed; OncoGe... [Published Nasdaq - Aug 22 2014]
OncoGenex Says Lung Cancer Drug Trial Will Cont... [Published BioPortfolio - Aug 22 2014]
OncoGenex Phase 3 ENSPIRIT Trial Continuing As ... [Published FinanzNachrichten.de - Aug 22 2014]
OncoGenex Pharmaceuticals Inc announces update ... [Published Reuters - Aug 21 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published Benzinga.com - Aug 21 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published Barchart - Aug 21 2014]
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published PR Newswire: Health - Aug 21 2014]
OncoGenex Pharmaceuticals CMO Cindy Jacobs Unlo... [Published American Banking News - Forex - Aug 15 2014]
OncoGenex Pharmaceuticals CMO Sells $17,911 in ... [Published American Banking News - Aug 15 2014]
OncoGenex Pharmaceuticals CEO Unloads $58,141 i... [Published American Banking News - Forex - Aug 15 2014]
Why Raptor Is Down, Despite Possibility of New ... [Published TheStreet.com - Aug 14 2014]
Why Raptor Is Down, Despite Possibility of New ... [Published The Street Latest - Aug 14 2014]
4 Stocks Under $10 Making Big Moves [Published The Street Latest - Aug 08 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published PR Newswire: Health - Aug 07 2014]
OncoGenex Pharmaceuticals Announces Appointment... [Published PR Newswire: General Business - Aug 07 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
OncoGenex Announces Update on Phase 3 ENSPIRIT ... [Published PR Newswire: Health - Aug 21 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), ...
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published PR Newswire: Health - Aug 07 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results.Clinical Developments and ...
OncoGenex Pharmaceuticals Announces Appointment... [Published PR Newswire: General Business - Aug 07 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO).  John Bencich, an experienced ...
OncoGenex to Report Financial Results for Secon... [Published PR Newswire: Health - Jul 24 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, July 24, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2014 financial results will be released on Thursday, August 7, 2014, and that ...
OncoGenex Announces Cedar™ Clinical Trial Evalu... [Published PR Newswire: Health - Jul 01 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, July 1, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating ...
1 2 3

Press Releases

sort by: Date | Relevance
OncoGenex Announces Completion of Patient Enrol... [Published Financial Services - Sep 16 2014]
OncoGenex Pharmaceuticals Announces Pricing of ... [Published Financial Services - Jun 26 2014]
OncoGenex Pharmaceuticals, Inc. Reports Financi... [Published Financial Services - Apr 30 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.